German-Korean Workshop

Mechanisms of Protein Aggregation in Neurodegenerative Diseases

Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by a progressive neuronal loss and cognitive decline. The most prominent members of this class of diseases are Parkinson’s disease, Alzheimer’s disease and frontotemporal dementia. Although these disorders manifest in distinct symptoms, they all share one common neuropathological hallmark: the abnormal accumulation and deposition of specific proteins either inside or outside of neurons within certain brain areas. Consequences of protein aggregation are the loss of physiological protein function as well as the gain of cytotoxic properties inducing neuronal death. To date, the mechanisms that drive protein aggregation are not completely understood, and there is no effective therapy available that could stop or at least slow down the progressive course of neurodegenerative diseases.

This workshop will highlight the molecular mechanisms underlying pathological protein aggregation leading to neurodegeneration and present current research on the development of novel therapeutic strategies in the treatment of neurodegenerative diseases.


For further details please contact: Dr. Josephine Labus

Download Workshop Flyer

Program - MHH, Lecture Hall N - June 22nd, 2022

10:30 – 10:40 Welcome
Frank Bengel (Dean of Research - MHH)
10:40 – 10:45 Introduction
Evgeni Ponimaskin
10:45 – 11:20 Tau-targeted therapeutics for the treatment of Alzheimer‘s disease
Ae Nim Pae
11:20 – 11:45 Targeting neural proteoglycans to control protein aggregation in aeging and neurodegenerative diseases
Alexander Dityatev
11:45 – 12:10 Tau-BiFC platform to visualize neurotoxic Tau species in the brain
Yun Kyung Kim
12:10 – 12:35 Targeting the serotonin receptor 7 ameliorates Tau pathology and memory deficits
Evgeni Ponimaskin
12:35 – 13:45 LUNCH BREAK
13:45 – 14:20 Clinical trials in Synucleinopathies and Tauopathies
Günter Höglinger
14:20 – 14:45 Modulation of inflammation and glial activation as therapeutic strategy in amyotrophic lateral sclerosis
Susanne Petri
14:45 – 15:10 Tau acetylation induced by HDAC inhibitors
Sungsu Lim
15:10 – 15:35 The role of serotonin receptors in TDP-43 aggregation
Josephine Labus
15:35 – 16:00 COFFEE BREAK
16:00 – 16:35 Super-resolution microscopy informs on the molecular architecture of alpha-synuclein inclusions in model systems and in the human brain
Tiago Outerio
16:35 – 17:00 Novel therapeutics for Synucleinopathies, progress towards predictive validity of preclinical trials
Franziska Richter Assencio
17:00 – 17:25 Nuclear bodies and aggregates in SMA and ALS
Tobias Schüning
17:25– 17:30 Concluding remarks
Evgeni Ponimaskin

Funded by

German-Korean Funding Programme for Joint Workshops & Research Visits.